Characterization of the expression of the ALK receptor tyrosine kinase in mice
- PMID: 16458083
- DOI: 10.1016/j.modgep.2005.11.006
Characterization of the expression of the ALK receptor tyrosine kinase in mice
Abstract
Anaplastic Lymphoma Kinase (ALK), a receptor tyrosine kinase, was first described as the fusion product causing a subtype of non-Hodgkin's lymphoma. To date Alk has been reported to be mainly expressed in CNS and other parts of the brain. Here we describe an extensive characterization of the mRNA and protein expression of ALK during mouse development. We show that mRNA and ALK protein show overlapping expressing patterns in specific regions of the central and the peripheral nervous systems. Furthermore, ALK is also expressed in the eye, nasal epithelium, olfactory nerve, tongue, skin, tissue surrounding the esophagus, stomach and midgut but not the hindgut. Expression of ALK is also found in testis and ovary.
Similar articles
-
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.Oncogene. 1997 Jan 30;14(4):439-49. doi: 10.1038/sj.onc.1200849. Oncogene. 1997. PMID: 9053841
-
Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma.Exp Mol Pathol. 2009 Apr;86(2):121-6. doi: 10.1016/j.yexmp.2008.11.012. Epub 2008 Dec 14. Exp Mol Pathol. 2009. PMID: 19135051
-
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22. Hum Pathol. 2009. PMID: 19386350
-
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Eur J Cancer. 2010. PMID: 20451371 Review.
-
Translocations involving anaplastic lymphoma kinase (ALK).Oncogene. 2001 Sep 10;20(40):5623-37. doi: 10.1038/sj.onc.1204594. Oncogene. 2001. PMID: 11607814 Review.
Cited by
-
Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.Metab Brain Dis. 2013 Sep;28(3):355-66. doi: 10.1007/s11011-013-9401-7. Epub 2013 Apr 2. Metab Brain Dis. 2013. PMID: 23543207 Free PMC article. Review.
-
Comment on "ALK is a therapeutic target for lethal sepsis".Sci Transl Med. 2018 Dec 12;10(471):eaar4321. doi: 10.1126/scitranslmed.aar4321. Sci Transl Med. 2018. PMID: 30541790 Free PMC article.
-
Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia.Front Oncol. 2019 Apr 16;9:275. doi: 10.3389/fonc.2019.00275. eCollection 2019. Front Oncol. 2019. PMID: 31058082 Free PMC article.
-
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001. Cancer Cell. 2012. PMID: 22789543 Free PMC article.
-
Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.Sci Rep. 2016 Sep 8;6:32682. doi: 10.1038/srep32682. Sci Rep. 2016. PMID: 27604320 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases